1,847 Shares in Gilead Sciences, Inc. $GILD Bought by Triad Wealth Partners LLC

Triad Wealth Partners LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,847 shares of the biopharmaceutical company’s stock, valued at approximately $205,000.

A number of other institutional investors and hedge funds also recently modified their holdings of GILD. Mirae Asset Global Investments Co. Ltd. increased its holdings in Gilead Sciences by 8.2% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 556,766 shares of the biopharmaceutical company’s stock worth $61,729,000 after buying an additional 42,128 shares during the last quarter. Cornell Pochily Investment Advisors Inc. increased its holdings in shares of Gilead Sciences by 24.8% during the 2nd quarter. Cornell Pochily Investment Advisors Inc. now owns 11,812 shares of the biopharmaceutical company’s stock valued at $1,310,000 after acquiring an additional 2,349 shares during the last quarter. J2 Capital Management Inc increased its holdings in shares of Gilead Sciences by 58.9% during the 2nd quarter. J2 Capital Management Inc now owns 3,864 shares of the biopharmaceutical company’s stock valued at $428,000 after acquiring an additional 1,432 shares during the last quarter. ASR Vermogensbeheer N.V. increased its holdings in shares of Gilead Sciences by 3.1% during the 2nd quarter. ASR Vermogensbeheer N.V. now owns 107,590 shares of the biopharmaceutical company’s stock valued at $11,928,000 after acquiring an additional 3,277 shares during the last quarter. Finally, CHURCHILL MANAGEMENT Corp increased its holdings in shares of Gilead Sciences by 277.3% during the 2nd quarter. CHURCHILL MANAGEMENT Corp now owns 163,496 shares of the biopharmaceutical company’s stock valued at $18,127,000 after acquiring an additional 120,165 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on GILD. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Rothschild & Co Redburn increased their target price on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a research note on Tuesday, August 19th. Finally, Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $117.17.

Gilead Sciences Stock Up 1.9%

NASDAQ:GILD opened at $112.69 on Friday. Gilead Sciences, Inc. has a 12-month low of $83.98 and a 12-month high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The firm has a market capitalization of $139.83 billion, a P/E ratio of 22.45, a P/E/G ratio of 0.77 and a beta of 0.34. The stock’s fifty day simple moving average is $114.34 and its 200-day simple moving average is $109.94.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences’s payout ratio is currently 62.95%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the transaction, the insider owned 113,193 shares of the company’s stock, valued at $12,855,329.01. The trade was a 2.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at approximately $18,120,661.35. This trade represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 82,000 shares of company stock valued at $9,402,130. 0.27% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.